Alzheimer’s Disease Treatment Market by Drug Class (API) – Acetylcholinesterase Inhibitors (Donepezil, Galantamine, Rivastigmine), Immunoglobulin (Gammagard Liquid), N-Methyl-Daspartate (NMDA) Receptor Antagonist (Memantine) and Forecast 2017-2021

Alzheimer’s Disease Treatment Market by Drug Class (API) – Acetylcholinesterase Inhibitors (Donepezil, Galantamine, Rivastigmine), Immunoglobulin (Gammagard Liquid), N-Methyl-Daspartate (NMDA) Receptor Antagonist (Memantine) and Forecast 2017-2021

Alzheimer disease (AD) is an insidious, progressive and irreversible brain disorder. Its incidence is highest in people aged over 65, a cohort forecast to grow by 62% between 2015 and 2030 to around 1 billion worldwide. In 2015, an estimated 5.1 million people in the United States who are aged 65 or older live with AD. By 2050, this number is predicted to increase to approximately 13.8 million. Although, the cause of AD is not fully understood, current treatments for AD aim to maintain functional capability while slowing or delaying symptoms. The approved compounds for the treatment of AD include the acetylcholinesterase (AChE) inhibitors donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne/Reminyl) and tacrine (Cognex) as well as the NMDA (N‑methyl-d‑aspartate) receptor antagonist memantine (Namenda/Axura). Currently, discounting university and public research programmes, 102 drugs are in clinical trials for the treatment of AD. These mainly consist of neuromodulatory signalling or Aβ-targeting therapies. Therapies that target neuromodulatory signalling include nicotinic acetylcholine receptor (nAChR) antagonists and AChE inhibitors, serotonergic therapies (that is, 5-hydroxytryptamine 4 (5‑HT4) agonists or 5‑HT6 antagonists), muscarinic receptor agonists and histamine receptor 3 (H3) antagonists. These are all thought to have limited clinical and commercial potential, as clinical trials have so far not shown any clear improvement in the efficacy of these drugs compared to currently approved drugs in this category. The mode of action of these drugs mainly include APP metabolism, Aβ aggregation/clearance, immune response modulator, microtubular/structural targets, neuromodulator signaling, neurotropic, and others.

The global Alzheimer’s disease treatment market segmentation is based on drug class (API) – acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine), immunoglobulin (gammagard liquid), N-methyl-daspartate (NMDA) receptor antagonist (memantine).

The global Alzheimer’s disease treatment market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global Alzheimer’s disease treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global Alzheimer’s disease treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global Alzheimer’s disease treatment market and profiled in this report include Abbott Laboratories, AC Immune, Affiris, AstraZeneca, Baxter International, Biogen Inc., Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen Pharmaceuticals (Johnson & Johnson), Lundbeck, Merck & Co., Neurim Pharmaceuticals, Novartis, Pfizer, Roche (Genentech), TauRx Therapeutics, vTv Therapeutics, and Warner-Lambert.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Alzheimer’s Disease Treatment Market

1. Drug Class (API)
1.1. Acetylcholinesterase (AChE) Inhibitors
1.1.1. Donepezil
1.1.2. Galantamine
1.1.3. Rivastigmine
1.2. Immunoglobulin
1.2.1. Gammagard Liquid
1.3. N-Methyl-Daspartate (NMDA) Receptor Antagonist
1.3.1. Memantine

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Abbott Laboratories
3.2. AC Immune
3.3. Affiris
3.4. AstraZeneca
3.5. Baxter International
3.6. Biogen Inc.
3.7. Bristol-Myers Squibb
3.8. Eisai
3.9. Eli Lilly
3.10. Janssen Pharmaceuticals (Johnson & Johnson)
3.11. Lundbeck
3.12. Merck & Co.
3.13. Neurim Pharmaceuticals
3.14. Novartis
3.15. Pfizer
3.16. Roche (Genentech)
3.17. TauRx Therapeutics
3.18. vTv Therapeutics
3.19. Warner-Lambert

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*